NFA
ALXN

Nuveen Fund Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Nuveen Fund Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,966
Closed -$219K – 242
2018
Q1 		$219K Sell
1,966
-148
-7% -$17.7K 0.1% 219
2017
Q4 		$253K Sell
2,114
-2,897
-58% -$353K 0.07% 256
2017
Q3 		$703K Sell
5,011
-716
-13% -$97.3K 0.14% 184
2017
Q2 		$697K Sell
5,727
-5,724
-50% -$666K 0.11% 218
2017
Q1 		$1.39M Sell
11,451
-2,168
-16% -$280K 0.18% 171
2016
Q4 		$1.67M Sell
13,619
-4,503
-25% -$551K 0.24% 138
2016
Q3 		$2.22M Sell
18,122
-963
-5% -$124K 0.31% 110
2016
Q2 		$2.23M Buy
+19,085
New +$2.71M 0.34% 94

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nuveen Fund Advisors's ALXN Position: Q2 2018 in Review

Nuveen Fund Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 1,966 shares — an estimated $219K sold.

Nuveen Fund Advisors first reported a position in ALXN in Q2 2016 and held it in 8 quarters. The position peaked at $2.23M in Q2 2016. 600 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • Nuveen Fund Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Nuveen Fund Advisors sold 1,966 Alexion Pharmaceuticals shares in Q2 2018, an estimated $219K.
  • Nuveen Fund Advisors first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 8 quarters.
  • Nuveen Fund Advisors's Alexion Pharmaceuticals position peaked at $2.23M in Q2 2016.
  • 600 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Nuveen Fund Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.